education conference |
||||
|
News for 12-Apr-26 Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General |
The Best education conference websiteAll the education conference information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best education conference site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
education conference
How do we know they're the best education conference sites for you to visit? Because we looked at all of them. Well we think we did. We where up to our knees in education conference information. And we didn't just look. We carefully worked our way through them until we came up with the leading places for you to visit. Why have we done this? Well if your new to the internet or are even an advanced user, you will soon find out that searching for things like education conference on the net can be very time consuming and even exhausting. That's why we have conducted research and compiled this website to try and make it easier for you to find the most relative and useful information on education conference today. education conference
Many websites claim that they use information to personalize your experience on the site. For instance, if a education conference site learns that you are interested in education conference, the next time you visit the site, you might be presented with an article or advertisements for that and related products. But some education conference websites sell this information to marketers, which means that you may find yourself receiving unwanted catalogs from garden suppliers. Our preferred retailer does not do this. We feel so confident that your education conference shopping experience will be a good one that we have built this site so that you can go straight to the prime education conference retailer without wasting a lot of time checking out vast numbers of very ordinary providers. Class of Drugs Brings Hope to Cancer Patients by: ARA Content
(ARA) - This is an exciting time in cancer research. Recent information on angiogenesis -- the growth of new blood vessels -- is providing researchers opportunities to find new ways to slow or stop a tumor's growth by cutting off the blood supply it needs. Angiogenesis performs a critical role in the development of cancer. To grow, solid tumors need oxygen and nutrients provided by new blood vessels. Once a vascular network has been generated, cancer cells can also invade the rest of the body, a process called metastasis. Currently, researchers believe that more than 90 percent of all cancer cases are angiogenesis-dependent. The good news is that a novel class of drugs, which acts as angiogenesis inhibitors, shows great potential in fighting more than 20 different diseases, including many types of cancer. These "anti-angiogenesis" drugs being developed and tested block the formation of new blood vessels, starving cancerous cells and stopping tumor growth. One drug being tested, Neovastat, was discovered in 1994 and is derived from cartilage tissue. Neovastat is the only angiogenesis inhibitor being developed in the biotechnology and pharmaceutical universe that has four mechanisms of action to combat blood vessel growth. Furthermore, Neovastat is taken orally, making it convenient for patients who need long-term treatment, and it has shown minimal side effects in clinical trials. This means that unlike standard chemotherapy, Neovastat is not likely to interfere with a patient's immune system, or cause adverse gastrointestinal symptoms or hair loss. In addition, because most cancer cells are genetically unstable and more prone to mutations, resistance is a major problem with many chemotherapy agents. But since anti-angiogenesis drugs target normal endothelial cells that are not genetically unstable, drug resistance is less likely to develop and has not been a problem so far in clinical trials. Another hope is that angiogenesis inhibitors can be used in combination with therapies that directly target tumor cells. Because anti-angiogenic drugs and chemotherapy are aimed at different cellular targets, it is possible that the combination will prove even more effective than either therapy is as a stand-alone. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer for which there are urgent needs for new therapies. For multiple myeloma, the second most common form of blood cancer, the drug is in phase two trials with 125 patients in the United States, Canada and Europe. This trial should be completed by the end of 2002. For progressive renal cell carcinoma, the drug is in phase three trials with 280 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a phase three trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess test results and make decisions on approval. Neovastat is being developed by Aeterna Laboratories of Quebec, Canada. For more information about current trials, call (888) 349-3232. If you are an oncologist, contact Claude Hariton, PhD, vice president of Clinical and Regulatory Affairs, (418) 652-8525, Ext. 306. To learn more about anti-angiogenesis and Aeterna Laboratories, visit the Aeterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.
|
|||
|
http://www.medmeet.com/ |
||||
| MD Meet Take It Correctly Medical Newscast |